Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.53 |
| ▸ | RXRB | P28702 | 5/20 | 0.51 |
| ▸ | RXRA | P19793 | 4/20 | 0.51 |
| ▸ | RXRG | P48443 | 3/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.49 |
| ▸ | HPD | P32754 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16844582 | 0.91 | MAPT (0.49) | MAOAMAOBBRD4RXRBRXRA | |
| SCHEMBL34466352 | 0.84 | L3MBTL1 (0.45) | MAOAMAOBBRD4RXRBRXRA | |
| SCHEMBL29473827 | 0.83 | MAPT (0.50) | MAOBBRD4RXRBRXRARXRG | |
| SCHEMBL16388131 | 0.83 | MAPT (0.50) | MAOBBRD4RXRBRXRARXRG | |
| SCHEMBL12634774 | 0.79 | ABCB1 (0.44) | MAOAMAOBBRD4MAPTMAPK1 | |
| SCHEMBL7336863 | 0.79 | MAOB (0.56) | MAOAMAOBBRD4HPD | |
| SCHEMBL16397981 | 0.78 | RXRB (0.72) | MAOAMAOBBRD4RXRBRXRA | |
| SCHEMBL10585250 | 0.78 | MAOA (0.49) | MAOAMAOBBRD4RXRBRXRA | |
| SCHEMBL29320880 | 0.78 | ABCB1 (0.44) | MAOAMAOBBRD4RXRBRXRA | |
| SCHEMBL24459314 | 0.77 | MAOA (0.51) | MAOAMAOBBRD4HPDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239761-A1 | BICYCLIC PHENOL COMPOUNDS AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239761-A1 | BICYCLIC PHENOL COMPOUNDS AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-0606661-B1 | Octahydrophenanthrene derivatives and their use as NMDA-Antagonists | HOFFMANN LA ROCHE (CH) | 1997-03-12 | — | — | EP | disclosed |
| US-5385947-A | For prevention of nerve damage due to reduction of blood or oxygen supplies | HOFFMANN-LA ROCHE INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0606661-A1 | Octahydrophenanthrene derivatives and their use as NMDA-Antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1994-07-20 | — | — | EP | disclosed |
| US-4420480-A | PARKINSONISM, DEPRESSION, HYPOTENSIVES | MERCK & CO., INC. (US) | 1983-12-13 | — | — | US | disclosed |
| EP-0080115-A2 | Hexahydronaphth(1,2-b)-1,4-oxazines, process for their preparation and pharmaceutical formulation containing them | MERCK & CO. INC. (US) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239761-A1 | BICYCLIC PHENOL COMPOUNDS AND USE THEREOF | CYP3A43, CYP11B2, UGT2B7 | MAOA 320/4885MAOB 135/4885BRD4 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.